Pliant Therapeutics Q1 2021 Earnings Report
Key Takeaways
Pliant Therapeutics reported a net loss of $22.9 million for the first quarter of 2021, compared to a net income of $11.0 million for the prior-year quarter. Research and development expenses increased to $18.5 million, and general and administrative expenses rose to $6.6 million. As of March 31, 2021, the company had $264.1 million in cash, cash equivalents, and short-term investments.
PLN-74809 Phase 2a PET imaging trial preliminary data expected in the first half 2021.
PLN-74809 Phase 2a INTEGRIS trial in idiopathic pulmonary fibrosis (IPF) continued to build momentum, currently on track to complete enrollment by the end of 2021.
PLN-74809 Phase 2a INTEGRIS trial in primary sclerosing cholangitis (PSC) continued to advance, currently on track to complete enrollment in the first half 2022.
Successful completion of PLN-1474 Phase 1 trial and transfer of PLN-1474 to Novartis.
Pliant Therapeutics
Pliant Therapeutics
Forward Guidance
The Company believes it has sufficient funds to meet its operating and capital requirements into 2023.